TLDR: Jon Friis, CEO of Miiskin, details how generative AI, backed by a $200,000 Danish Innovation Fund grant, is set to transform dermatology. The technology will automate non-clinical tasks like patient intake, communication, and compliance, significantly reducing administrative burdens for clinicians. This integration has already cut initial assessment wait times from over 30 days to 24-48 hours, aiming to expand access to care, prevent burnout, and reach 100 million people by 2040.
In a recent Q&A with Dermatology Times, Jon Friis, founder and CEO of the online platform Miiskin, outlined the transformative potential of generative artificial intelligence (AI) in clinical dermatology workflows. Miiskin is spearheading an initiative to integrate AI into its platform, supported by a $200,000 grant from the Danish Innovation Fund, with the primary goal of alleviating administrative burdens on clinicians and enhancing patient access to specialized care.
Friis emphasized that Miiskin’s strategy focuses on embedding AI into every step of the digital dermatology experience, allowing providers to dedicate more time to patient care and less to administrative tasks. The grant will specifically fund the integration of generative AI to automate repetitive, non-clinical tasks such as patient intake, organizing patient-submitted information, and streamlining communication between patients and providers. This approach is designed to adapt to existing dermatologist workflows rather than forcing new practices.
According to Friis, generative AI will significantly improve the timing of clinical tasks. It will handle time-consuming activities like organizing images and patient histories, summarizing intake data, and drafting routine communications. This automation is expected to reduce the time dermatologists spend preparing for or following up on each case. Furthermore, AI has the potential to simplify and enhance the entire medication prescribing workflow, leading to reduced administrative burden and improved prescription speed. As a testament to its current impact, Friis noted that patients using Miiskin have already seen the wait time for an initial dermatology assessment drastically cut from over 30 days to just 24 to 48 hours. This efficiency allows dermatologists to scale their practices more effectively, manage higher patient volumes, and ultimately make specialist care more accessible across communities.
Beyond efficiency, AI is also poised to become a crucial compliance assistant. Friis explained that AI can automatically flag missing or incomplete details in documentation or treatment plans, identify inconsistencies, and verify that prescribed medications align with recorded diagnoses by leveraging large, anonymized data sets. This function serves to reduce errors, save time, and instill greater confidence in dermatologists that their records meet regulatory standards, acting as a real-time aid rather than replacing medical judgment.
Addressing concerns about patient security and data privacy, Friis affirmed that Miiskin operates under strict HIPAA compliance. All AI initiatives are designed within the same robust data privacy framework, ensuring patient data is encrypted during transmission, stored securely, and never disclosed to third parties without authorization. Transparency and ethics are core to Miiskin’s approach, aligning with the Danish Innovation Fund’s evaluation criteria.
One of the biggest challenges in implementing AI in healthcare, as highlighted by Friis, is ensuring that AI never compromises medical liability or decision-making, and that clinicians maintain full control. Miiskin tackles this by initially focusing on practical, non-clinical tasks where AI can deliver immediate value, thereby building trust and reinforcing the dermatologist’s role as the ultimate decision-maker.
The feedback from dermatologists has been overwhelmingly positive, as the AI directly addresses their desire for more patient interaction and less administrative work. Friis’s message to skeptical clinicians is clear: the goal is to augment, not replace, clinical expertise, by reducing friction in daily tasks.
Also Read:
- SDAIA to Host Seminar on Generative AI’s Future Landscape
- Novel Training Approaches for Diffusion Models Significantly Enhance Generative AI Efficiency
Looking ahead, Friis envisions a future within the next 5 to 10 years where every dermatology consultation begins digitally. Patients will submit high-quality images and structured information pre-visit, with AI organizing and summarizing this data for clinicians. This integration of AI and telehealth is expected to expand access to dermatology at scale, reduce global wait times, and combat clinician burnout. Miiskin’s ambitious vision is to provide expert dermatological care to 100 million people by 2040, with AI serving as a pivotal driver in achieving this goal.
